ALK-Abello, S.A.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Copenhagen Denmark (1923)

Organization Overview

First Clinical Trial
1996
NCT00135642
First Marketed Drug
2015
ciprofloxacin (cipro)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ALK ABELLO | ALK-Abelló | ALK-Abello A/S | ALK-Abelló A/S | ALK-Abelló A/S, Boege Alle 6-8, 2970 Hoersholm, Denmark | ALK Nordic A/S, Danmark Filial | ALK-SCHERAX Arzneimittel GmbH | Center Laboratories, Inc. | Clinical Research Director, ALK-Abelló, S.A.

Active Ingredients

Marketed Drugs (1)

ciprofloxacin (cipro) (2015)

Drugs in Phase 4 Trials (9)

albuterol (proventil) (4 trials)

epinephrine (levophed) (1 trial)

grazax (9 trials)

house dust mite allergen (11 trials)

mk-3641 (1 trial)

mk-7243 (1 trial)

short ragweed pollen allergen (4 trials)

sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract (Oralair) (1 trial)

tree 12 sq-bet (1 trial)

Drugs in Phase 3 Trials (17)

Key: ALK-Abello, S.A. (15) Acquired (2)

acetaminophen (tylenol) (3 trials)

birch pollen allergen extract (2 trials)

budesonide (rhinocort) (1 trial)

desloratadine (clarinex) (2 trials)

fluticasone (cutivate) (2 trials)

formoterol (foradil) (1 trial)

loratadine (claritin) (2 trials)

mometasone (elocon) (2 trials)

olive allergen (1 trial)

olopatadine (patanol) (2 trials)

pangramin (1 trial)

p. pratense pollen extract (10 trials)

prednisone (meticorten) (3 trials)

sch 39641 (3 trials)

sch 697243 (3 trials)

timothy grass pollen allergen extract (Grastek) (7 trials)

tree allergen (2 trials)

Drugs in Phase 2 Trials (9)

avanz salsola (1 trial)

cat epidermis allergen (1 trial)

cs02 (1 trial)

cupressus arizonica (1 trial)

dupilumab (dupixent) (1 trial)

metformin (glucophage) (1 trial)

oak tree allergen (1 trial)

osiris (1 trial)

verapamil (calan) (1 trial)

Drugs in Phase 1 Trials (4)

acetylcysteine (mucomyst) (1 trial)

betula verrucosa allergen extract (1 trial)

mk-8237 (1 trial)

peanut allergen (1 trial)

Drugs in Other Trials (2)

alutard (1 trial)

dog hair extract (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 4)

Cluster Headache (Phase 2)

Conjunctivitis (Phase 4)

Conjunctivitis, Allergic (Phase 2)

Dermatitis (Phase 3)

Dermatitis, Atopic (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Eczema (Phase 3)

Headache (Phase 2)

Hypersensitivity (Phase 3)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Seasonal (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 65
  • # of Trial APIs: 41